• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - translational medicine
Tag:

translational medicine

Health

Micro- and Nanoplastics Linked to Increased Heart Attack Risk

by Chief Editor July 15, 2026
written by Chief Editor

Patients who experienced a serious heart attack were significantly more likely to have micro- and nanoplastics (MNPs) in their blood compared to those with chronic ischemic heart disease or healthy coronary arteries, according to a study published in the European Heart Journal. Researchers from Sapienza University of Rome, the University of Verona, and the University of Campania “Luigi Vanvitelli” found that 84% of heart attack patients possessed these plastic particles, suggesting a potential link between environmental pollutants and cardiovascular events.

The Link Between Environmental Exposure and Heart Health

The study, titled “Micro- and nano-plastics in the coronary circulation and air pollution exposure in ischemic heart disease presentation,” analyzed 61 patients undergoing coronary angiography. Researchers found that MNP presence was not uniform across patient groups. While 84% of heart attack patients showed detectable plastic particles, that figure dropped to 40% for those with chronic ischemic heart disease and 32% for the control group with normal coronary arteries.

Dr. Emanuele Barbato, the study’s senior author and director of the Cardiology Unit at Sant’Andrea University Hospital, noted that while the findings do not definitively prove that microplastics cause heart attacks, they reveal a strong association. “Our findings suggest that smoking might make it easier for micro and nanoplastics to enter the blood stream via the lungs,” Barbato stated, adding that air pollution likely acts through similar biological pathways.

Did you know?
The most common type of plastic identified in the blood of study participants was polyethylene (PE), a polymer frequently used in consumer packaging. It was present in 97% of all patients who had detectable levels of MNPs.

How Smoking and Pollution Influence MNP Accumulation

The data suggests that lifestyle and environmental factors significantly increase the risk of plastic accumulation in the circulatory system. Patients exposed to higher long-term levels of PM2.5 air pollution were more likely to harbor microplastics. The impact of smoking was even more pronounced: smokers were six times more likely to have these particles in their blood than non-smokers.

According to the research team, including Dr. Pasquale Paolisso of Sant’Andrea Hospital, the combination of these factors creates a high-risk profile. All patients in the study who were smokers and exposed to high levels of air pollution showed plastic particles in their blood, compared to only 12.5% of patients who neither smoked nor faced high pollution levels.

Biological Mechanisms and Future Cardiovascular Risks

Once thought to be inert, MNPs are increasingly viewed by researchers as biologically active pollutants. The study authors suggest these particles may contribute to the pathophysiology of cardiovascular disease by promoting the development of atherosclerotic plaques and triggering inflammation. Evidence of this includes higher concentrations of IL-6 and TNF-α—markers of inflammation—in patients with detectable MNPs.

An interview with Emanuele Barbato – Introducing the Improving Heart Function (iHF) initiative

Dr. Andreas Daiber of the University Medical Centre of the Johannes Gutenberg University, Mainz, provided an editorial perspective alongside the study. He and his colleagues emphasized that environmental stressors rarely act in isolation. “Individuals are exposed to multiple environmental stressors simultaneously, including air pollution, noise, chemical contaminants, plastics, and climate-related stressors,” Daiber noted. This “exposome” approach suggests that reducing the burden of environmental pollutants is becoming as vital to heart health as managing traditional risk factors.

Pro Tip:
While individual MNP exposure is difficult to measure, the research team suggests that public health policies aimed at reducing air pollution and tobacco exposure remain effective strategies for lowering the risk of environmental cardiovascular hazards.

Frequently Asked Questions

Can microplastics directly cause a heart attack?

The current study does not prove a direct causal link. However, researchers identified a strong association between MNP presence in the blood and the severity of cardiovascular disease, suggesting they may contribute to inflammation and plaque progression.

What types of plastics were found in the patients?

Polyethylene (PE) was the most frequently identified polymer, appearing in 97% of patients who had detectable plastic particles in their blood.

Are these findings applicable to the general population?

The study specifically examined patients undergoing angiography for suspected coronary artery disease. Further clinical investigations are needed to understand how these particles affect the broader population and to validate the long-term health implications.


Have you considered how your environment impacts your long-term heart health? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on cardiovascular research.

July 15, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

Genetic Map Breakthrough Could Reverse Bone Loss

by Chief Editor July 13, 2026
written by Chief Editor

An international research team has mapped the cells and genes regulating bone formation and loss, identifying blood vessel cells as a driver of skeletal repair. Published in Nature Genetics, the study utilized genomic sequencing and data from 500,000 individuals to discover hundreds of previously unknown genes linked to bone health, offering new targets for treating conditions like osteoporosis and cancer metastasis.

Mapping the Cellular Blueprint of Bone

The human skeleton undergoes a complete renewal process approximately every decade. Despite this constant turnover, the specific cellular mechanisms governing bone health have remained poorly understood. According to Peter Croucher, PhD, of the Garvan Institute of Medical Research, current medical treatments generally focus on halting disease progression rather than actively rebuilding lost bone.

To address this, researchers employed single-cell RNA sequencing to analyze the interface between hard bone and bone marrow. This work identified 34 distinct cell groups. As Ryan Chai, PhD, noted, more than half of the genes identified in this analysis had never previously been associated with bone maintenance.

Did you know?

The human body replaces its entire skeleton roughly every 10 years. This continuous remodeling is the target for new therapies aimed at reversing skeletal damage.

The Role of Blood Vessels in Skeletal Integrity

A significant finding of the study is the previously underappreciated role of blood vessel cells in bone health. By integrating genetic and bone density data from the UK Biobank, researchers were able to pinpoint specific cell types that regulate both bone formation and bone loss.

John Kemp, PhD, associate professor at Mater Research, stated that these findings reveal how blood vessel cells contribute to the structural integrity of bone. This shift in understanding may change how clinicians approach skeletal diseases, such as osteogenesis imperfecta and severe osteoporosis, by targeting the vascular environment within the bone marrow.

Future Trends: Beyond Osteoporosis Treatment

The implications of this genetic map extend beyond traditional bone density disorders. Because bone marrow serves as a common site for dormant cancer cells to hide and later relapse, identifying the genes that drive bone turnover offers a new frontier in oncology.

According to Croucher, understanding these mechanisms provides a potential path to prevent cancer metastasis. The research team has made their data available through an open-access platform, allowing scientists worldwide to utilize these findings in the development of new medicines designed to rebuild bone tissue and neutralize the environments that support cancer spread.

Pro Tip:

Researchers are now focusing on therapeutic validation.

Frequently Asked Questions

How does this research change the treatment of osteoporosis?

Most existing drugs only stop bone loss. This research identifies specific genes and cells that could lead to new therapies capable of rebuilding lost bone mass.

🎥 BOX RALLIES RESEARCH FILMS – Professor Peter Croucher 🎥

Why are blood vessels important for bone health?

Data from the study shows that cells surrounding blood vessels are critical drivers of bone repair, a role previously underestimated in skeletal health.

Can this research help cancer patients?

Yes. Because bones are a common site for cancer metastasis, identifying the genes that regulate bone turnover may help clinicians prevent cancer cells from settling and remaining dormant in the bone.


Have questions about how these genetic breakthroughs might affect future bone health treatments? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates on medical research.

July 13, 2026 0 comments
0 FacebookTwitterPinterestEmail
Tech

AI-Powered Pan-Cancer Map Identifies Tertiary Lymphoid Structures

by Chief Editor May 29, 2026
written by Chief Editor

Beyond Presence: How a New “Immune Map” is Changing Cancer Prognostics

For years, oncologists have viewed Tertiary Lymphoid Structures (TLSs)—the immune system’s local command centers—as a simple “yes or no” biomarker. If they were present, the patient generally fared better. If they were absent, the outlook was often grimmer. But a groundbreaking study from The University of Texas MD Anderson Cancer Center is proving that this binary view is missing the bigger picture.

View this post on Instagram about Tertiary Lymphoid Structures, Anderson Cancer Center
From Instagram — related to Tertiary Lymphoid Structures, Anderson Cancer Center

By developing the first-ever pan-cancer spatial atlas of these structures, researchers have uncovered that it isn’t just about whether these “immune hubs” exist; it’s about their maturity, their location and their cellular neighborhood. This shift from simple detection to complex spatial analysis is poised to redefine how we predict treatment responses and patient outcomes.

Did you know? Researchers analyzed over 25,000 individual TLSs across 12 different cancer types. This massive dataset proves that the “maturity” of an immune structure is just as critical as its presence in fighting off tumor cells.

The Power of the “Composition Score”

The core of this new research lies in a sophisticated AI framework that moves beyond traditional pathology. Using routine hematoxylin and eosin (H&E) slides—the same images pathologists look at every day—the team created a TLS composition score. This score doesn’t just count the number of lymphoid structures; it evaluates their maturity and spatial relationship to tumor cells.

In clinical terms, this is a game-changer. By quantifying how “organized” a TLS is, clinicians can better stratify patients. Instead of a one-size-fits-all prognosis, doctors may soon be able to say, “Your immune system is currently building a highly effective response, or it needs a nudge to reach full maturity.”

Why Spatial Context Matters

Think of the tumor microenvironment (TME) like a city. A TLS located miles away from the “action” (the tumor) is far less effective than one embedded directly in the urban center. The MD Anderson study found that TLSs closer to tumor cells are associated with distinct signaling gradients, effectively acting as frontline bases for B cells and T cells to launch targeted attacks.

Prof. Wenyi Wang – MD Anderson Cancer Center, Houston, TX
Pro Tip: Look for future clinical trials that utilize “spatial omics.” This technology is rapidly evolving from a research tool to a diagnostic standard, allowing us to see the “social network” of immune cells in real-time.

The Future of Precision Immuno-Oncology

The ultimate goal here isn’t just better prediction—it’s therapeutic intervention. If we can identify patients whose TLSs are present but “immature,” the next frontier of cancer research will be finding ways to stimulate those structures to reach full, functional maturity.

The Future of Precision Immuno-Oncology
Dynamic Monitoring
  • Dynamic Monitoring: Could we use AI to track how TLSs evolve during immunotherapy?
  • Personalized Strategies: Could specific drugs be used to “recruit” immune cells to build TLSs where they are currently missing?
  • Scalability: Since this AI works on standard pathology images, it could be implemented in hospitals globally without the need for expensive, specialized equipment.

Frequently Asked Questions

What are Tertiary Lymphoid Structures (TLSs)?
TLSs are organized clusters of immune cells (B cells, T cells, and dendritic cells) that form within tumors to coordinate an attack against cancer cells.
How does this new AI help patients?
The AI provides a more accurate “composition score” than human observation alone, helping doctors predict which patients will respond best to immunotherapy and who might need alternative treatments.
Is this technology available in hospitals now?
Not yet. While the framework is highly scalable, it currently requires prospective clinical validation to ensure it can be safely integrated into standard hospital workflows.

The landscape of oncology is shifting toward a deeper understanding of the immune microenvironment. As we move from counting immune cells to mapping their spatial organization, we get one step closer to truly personalized cancer care.

What do you think about the role of AI in pathology? Does the prospect of AI-driven prognostic scoring make you feel more confident about the future of cancer treatment? Share your thoughts in the comments below or subscribe to our newsletter for the latest updates in immuno-oncology.

May 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Gene Therapy Reverses TDP-43 Neurodegeneration in Mice

by Chief Editor May 27, 2026
written by Chief Editor

A New Frontier in Brain Health: Beyond Protein Clearance

For decades, the search for treatments for Alzheimer’s, ALS, and frontotemporal dementia (FTD) has been dominated by a singular goal: clearing out toxic protein aggregates. Scientists have spent years trying to remove the “trash” from the brain, yet clinical success has remained frustratingly elusive.

A New Frontier in Brain Health: Beyond Protein Clearance
Researchers

Now, a paradigm shift is underway. Researchers at the University of California, San Diego are pioneering a new approach that focuses not on removing the toxic proteins, but on fortifying the neurons themselves. By boosting the brain’s intrinsic resilience, this strategy could change how we treat neurodegenerative diseases forever.

The TDP-43 Challenge

At the center of this research is TDP-43, a protein that, when misfolded, wreaks havoc on the brain. It is implicated in the vast majority of ALS cases and over half of all Alzheimer’s diagnoses. When TDP-43 goes rogue, it migrates to the wrong parts of the cell, disrupting communication and triggering a cascade of cellular decay.

The TDP-43 Challenge
Gene Therapy Reverses

Traditional therapies struggle because they often target the protein after the damage is already done. The UCSD team, led by Brian Head, PhD, is taking a different path: using gene therapy to bolster the cell’s internal defenses.

Pro Tip: Look for the rise of “resilience-based” therapies in clinical pipelines. Rather than focusing solely on protein clearance, these treatments aim to reinforce cellular structural integrity, offering a potential lifeline for patients with complex, multi-faceted neurodegenerative conditions.

SynCav1: A Breakthrough in Cellular Resilience

The study, published in Alzheimer’s & Dementia, highlights a gene called SynCav1. This gene encodes caveolin-1, a scaffolding protein that acts as a structural foundation for cellular signaling. By delivering SynCav1 via a modified AAV vector capable of crossing the blood-brain barrier, researchers were able to protect cognitive function in mouse models.

Why is this a big deal? Unlike many CNS therapies that require invasive brain surgery, this systemic approach could eventually be administered less invasively. The results were striking: the treatment preserved learning, memory, and even the structural integrity of mitochondria—the power plants of our cells.

Future Trends in Neurodegeneration Research

As we look toward the future of neurology, several key trends are emerging:

Haddee Q&A: UCSD Advanced Neurosciences Research Program
  • Crossing the Barrier: The development of advanced AAV vectors that effectively navigate the blood-brain barrier is opening doors to non-surgical gene therapies.
  • Multi-Level Protection: Future treatments will likely aim for “broad neuroprotection,” simultaneously stabilizing synapses, axons, and mitochondrial health rather than targeting a single symptom.
  • Precision Resilience: Identifying patients based on their specific proteinopathy profiles will allow for more tailored gene-therapy interventions.
Did you know? TDP-43 doesn’t just affect memory. It is a major driver of physical decline in ALS, meaning that therapies protecting neuronal resilience could have far-reaching benefits for both cognitive and motor functions.

Frequently Asked Questions

What is the primary difference between this therapy and traditional Alzheimer’s drugs?
Traditional drugs often attempt to “clear” toxic proteins (like amyloid or TDP-43). The SynCav1 approach aims to strengthen the neuron so it can withstand the presence of these proteins without failing.
Is this therapy currently available for humans?
No. The research is currently in the preclinical stage, meaning it has shown success in animal models and requires further rigorous testing before human clinical trials can begin.
How does SynCav1 cross the blood-brain barrier?
Researchers utilize modified adeno-associated virus (AAV) vectors, which are engineered to bypass the brain’s natural protective barrier, allowing the therapeutic gene to be delivered systemically.

Join the Conversation

The transition from “protein clearance” to “cellular resilience” represents one of the most exciting shifts in modern medicine. Do you believe gene therapy is the key to finally conquering neurodegeneration? Let us know your thoughts in the comments below, or sign up for our newsletter to stay updated on the latest breakthroughs in biotechnology and brain health.

Frequently Asked Questions
Alzheimer

May 27, 2026 0 comments
0 FacebookTwitterPinterestEmail

Recent Posts

  • Apple Overtakes Nvidia as World’s Most Valuable Company

    July 17, 2026
  • The True Cost of Raising Kids in LA: 2026 Price Map

    July 17, 2026
  • Ticket Prices: How Much Do They Cost?

    July 17, 2026
  • Invasive Urothelial Carcinoma: A Rare Case of Combined Obstructive Uropathy and Bowel Obstruction

    July 17, 2026
  • Trump Targets China in Pre-Midterm Strategy Shift

    July 17, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

© 2026 Newsy Today. All rights reserved.
For contact, advertising, copyright, issues email: [email protected]


Back To Top

For contact, advertising, copyright, issues email: [email protected]

Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World